Buchang Pharmaceutical
Provides pharmaceutical products, research, and sales in China
Buchang Pharmaceutical, founded in November, 2009 and headquartered in Heze, is a company integrating medical research, production, sales, diagnosis and treatment services and education. The founder is Zhao Tao. Listed on the SSE on November 18, 2016, the company's major shareholders are Buchan (Hong Kong) Holdings Limited, Shoucheng International (Hong Kong) Limited and North Haven TCM Holding Limited. Rivals that have direct and indirect competition with Buchang Pharmaceutical include JD Health, Ping An Good Doctor, Babyscripts, Conversa, etc.
Netease's revenue in the first quarter was 23.56 billion yuan, with an estimated 22.64 billion yuan.
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Taizhou: increase the amount of provident fund loan to 500000 yuan, and change the housing sales restriction from two years to one year
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
Haier Biomedical 'Smart Blood City Network' Lands in Brazil
Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.
Apr 15, 2024 03:45 PM
The Ukrainian delegation sent six people to participate in the Russian Ukrainian talks
Haitong Securities: the market contracted and rebounded, still focusing on defense strategy
D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline
EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.
Apr 12, 2024 06:05 PM